Despite great improvements in the ability to treat systemic lupus erythematosus (SLE) nephritis, management of nervous system manifestations of patients with SLE remains unsatisfactory. Nervous system involvement occurs in about 50% of all patients at some time during the course of their illness, with an impact on their lives which can vary from insignificant to disabling. Indications that the nervous system is involved include the organic brain syndrome (disorientation, forgetfulness, disturbances of attention), seizures, chorea, stroke, and frank episodes of psychosis. Controversy as to the best approach to patients with central nervous system (CNS) SLE surrounds the pathogenesis, diagnostic difficulties, and treatment. This article focuses on these three topics.
epilepsy, coma, stroke, chorea-athetosis, neurocognitive dysfunction, cerebellar ataxia, headache, cranial neuropathy, and transverse myelitis5 --a variety which is insufficiently accounted for by direct clinicopathological correlation. This is the first big controversy in CNS lupus: is one unifying disease mechanism responsible for this diversity of clinical presentations or do separate mechanisms play a role?
Hypotheses advanced to explain the spectrum of CNS manifestations associated with SLE may be divided into four categories: immune complex vasculitis; neurone reactive autoantibodies; thrombosis associated with antiphospholipid antibodies; and cytokine enhanced autoimmunity.
Pathogenesis
The pathogenesis of CNS SLE leads both to the observed histopathological findings'-3 and to the clinical manifestations; at the same time it forms the main target of treatment. In a landmark study, Johnson and Richardson' described the pathology of cerebral lupus. They found 80% of 24 postmortem brain specimens to be microscopically abnormal; multifocal microinfarcts and increased pericapillary microglial cells were the predominant abnormalities. Abnormalities of the brain vessels include a vasculopathy involving small arteries (< 100 ,um), in addition to fibrin thrombi occluding the lumens of affected vessels (fig 1) . Features Infrequently, the lesions may be restricted to the cerebellum and mid-brain. 4 The association of the microvascular lesions with microinfarcts suggested that occlusion of small vessels is the basis for the damage to the nervous system. While the histopathological features are straightforward, the clinical spectrum of CNS involvement is broad. However, until strict criteria for recognition of CNS SLE are laid down, reports correlating clinical findings with pathology, serological parameters, and radiology may be biased and unreliable, and it will not be possible to test treatment modalities rigorously.
Bruyn
It is not surprising, therefore, that uncertainty and controversy dominate the field of management of cerebral lupus. Should an SLE patient presenting with stroke be treated in a totally different way than a patient with organic brain syndrome? Merely for practical reasons, it might be sensible to classify CNS SLE into separate groups with various manifestations. 6 No controlled study of any treatment strategy has so far been conducted in neuropsychiatric lupus. The principles of treatment of cerebral lupus lupus are triple: anticoagulants, corticosteroids, and immunosuppressives (table 2) . Anticoagulants should be given for manifestations associated with hypercoagulability. Steroids are administered to reduce inflammation and the immune response. Finally, immunosuppressives, for example cyclophosphamide and azathioprine, suppress circulatory B and T lymphocytes, and autoantibody formation by B lineage cells in lymphoid tissues. Anticoagulation for whom? Since the elucidation of the role of antiphospholipid antibodies in thrombotic manifestations in SLE patients,39 41 growing agreement on anticoagulation has emerged steadily. Lupus patients simply with presence of these antibodies are currently not considered to be at high risk of developing thrombotic events and do not receive prophylactic anticoagulation. Patients with SLE and a history of bland stroke, however, have a 69% chance of a recurrent stroke.79 Therefore, recurrent cerebral thrombotic events-whether associated with antiphospholipid antibodies or not-are now important indications for initiating anticoagulation therapy.79 80 In all cases of stroke, cardiogenic emboli should be considered as possible causes as they form a major cause of stroke in lupus. Although consensus Eyanson et al reported two acutely ill patients who failed to respond to oral glucocorticoid therapy, but who responded dramatically to intravenous methylprednisolone pulse therapy. 86 Dutton et al reported three women with acute retrobulbar optic neuritis who responded to intravenous methylprednisolone therapy;87 the diagnosis of SLE, however, was not clearly established. More recently, new perspectives have arisen for the treatment of the rare complication, transverse myelitis, by pulse steroids followed by cyclophosphamide for a mean of six months. 88 Controversy attends the possible role of corticosteroids in the induction of psychosis and the facilitation of infection. Sergent et a189 retrospectively examined the effect of corticosteroids in 28 patients with 52 episodes of nervous system manifestations and found that 14 patients had 15 episodes of functional psychosis, possibly attributable to treatment. Five of the nine deaths in that study were attributable to infection. Since the patients received mean prednisone doses of more than 100 mg/day for prolonged periods, side effects should be anticipated. Glucocorticoids are now prescribed in much smaller doses than formerly used.7 In the study by O'Connor,90 of 11 previously psychotic patients who subsequently received steroids, only three had a recurrence of their psychoses. The eight patients who had no further psychotic episodes received essentially the same amount of corticosteroids as they had had at the time of their psychoses. That paper clearly showed that lupus patients are particularly prone to develop psychotic episodes independently of steroid therapy, although the latter may play some part.
Cytotoxic agents have been extensively studied in renal lupus during the past two decades. Treatment comprising oral azathioprine in combination with prednisone was better than prednisone alone in the management of lupus nephritis. No data exist on this drug in the management of CNS lupus. Another agent, cyclophosphamide, has also proved to be effective in lupus nephritis in combination with prednisone. In one open prospective trial, the effect of monthly intravenous infusions of cyclophosphamide to nine patients with lupus nephritis, cerebral lupus, or both, was studied;9' although CNS disease improved in a small number of patients, there were insufficient data to permit conclusions about the treatment of the neurological disease. Another study was of refractory CNS lupus in nine patients, six of whom had been unresponsive to high dose steroid therapy.92
Six patients had a complete and two a partial recovery; side effects were common, however. From these studies and others,7 and from unpublished personal observations, it seems that intravenous pulse cyclophosphamide therapy may be the best therapy for lupus patients with progressive deterioration in level of consciousness,7 acute psychosis or coma9" (GRV Hughes, personal communication).
Furthermore, in combination with intravenous pulse methylprednisolone it is the treatment of choice for transverse myelitis.88
Experimental therapies, including low dose methotrexate, cyclosporin, plasmapheresis, total lymphoid irradiation, anti-idiotypic antibodies, and intravenous IgG are the subject of too limited experience for it to be possible to recommend them at the present time.
Summary
What have we learned about CNS lupus in recent years? An enormous amount of knowledge on pathophysiology of antiphospholipid antibodies, in particular, has been gathered. Although hard evidence of a direct pathogenetic role of these antibodies in cerebral lupus is still lacking, it is generally felt that the multiple microinfarctions found in the brains of lupus patients are related to their presence. Better understanding of the pathogenesis of cerebral lupus will come from the study of experimental models, as it has been possible to develop an antiphospholipid antibody syndrome in mice. 93 Because no specific laboratory test for CNS lupus is yet available, diagnosing the condition remains a challenge to every clinician. Techniques including neuropsychometric testing, quantitative EEG, and SPECT scans have taught us more about cognitive dysfunction and psychosis in patients with SLE. These categories remain the most difficult to define.
The concept of hypercoagulability in SLE patients has diverted the direction of therapy from immunosuppression towards anticoagulation. It is of utmost importance that randomised trials are commenced in order to determine the optimal mode of anticoagulation for various groups of lupus patients. It will be necessary to conduct such trials under strict inclusion criteria, based on well defined patient categories. Such an enterprise will require international co-operation of investigators.
The specimens for microscopy were kindly provided by Prof F Eulderink, Department of Pathology, Academisch Ziekenhuis Leiden.
